Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1891-1897

  Calvo Villas, J M ^a   Martin A ^b   Conde, E ^c   Pascual, A ^d   Heras, I ^e   Varela, R ^f   de la Rubia, J ^g   Ramirez, M J ^h   Diez Martin J L ⁱ   Panizo, C ^j   Rodriguez Salazar M J ^k   Pascual, M J ^l   Donato, E M ^m   Gonzalez Barca E ⁿ   Caballero, M D ^o  

^a HOSPITAL GENERAL DE LANZAROTE   (Spain)

^b Hospital Provincial de Zamora   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL DE JEREZ   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^j UNIVERSITY CLINIC OF NAVARRA   (Spain)

^k HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^l HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^m HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁿ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^o HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; Rituximab; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 77956124153     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq035     Document Type: Article

References (24)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Mills W, Chopra R, Mcmillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 3: 588-595.
3. Nademanee A, Schmidt GM, O'Donnell MR et al. High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation during first complete remission adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992; 80: 1130-1134.
4. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
5. Kewalramani T, Nimer SD, Zelenetz AD et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673-679.
6. Kuittinen T, Wiklund T, Remes K et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol 2005; 75: 199-205.
7. Johnsen HE, Björkstrand B, Carlson K et al. Outcome for patients with leukaemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. Leuk Lymphoma 1996; 24: 81-91.
8. Vaishampayan U, Karanes C, Du W et al. Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation. Cancer Invest 2002; 20: 303-310.
9. Buchler T, Hermosilla M, Ferra C et al. Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation-experience from a single center. Hematol J 2003; 8: 145-150.
10. Paltiel O, Rubinstein C, Or R et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003; 31: 565-569.
11. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.
12. Vellenga E, van Putten WL, van 't Veer MB et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537-543.
13. Tsai D, Moore H, Hardy C et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 521-526.
14. Pan D, Moskowitz CH, Zelenetz AD et al. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J 2002; 8: 371-376.
15. Olivieri A, Lucesole M, Capelli D et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 627-636.
16. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783.
17. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Martín A, Conde E, Arnan M et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93: 1829-1836.
20. Gisselbrecht C, Schmitz N, Mounier N et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood 2007; 110 (Suppl): (Abstr 517).
21. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
22. Shimoni A, Hardan I, Avigdor A et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457-464..
23. Rapoport AP, Meisenberg B, Sarkodee-Adoo C et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002; 29: 303-312.
24. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.